Breadcrumb Home Business activities 麻豆社 BioCapital 麻豆社 BioCapital Portfolio ZIARCO Pharma ZIARCO Pharma Developed dermatological drugs, the lead being an H4 receptor antagonist tested in Atopic Dermatitis and Psoriasis patients. Relateret nyheder om ZIARCO Pharma 16 December 2016 Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited 15 June 2016 Ziarco Pharma Ltd: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients 17 May 2016 Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 2 March 2016 Ziarco Pharma Ltd: Appointment of Dr. Arvind Hundal as Chief Business Officer 5 February 2016 Phase 2a Psoriasis Study Initiated with Ziarco鈥檚 Lead Compound ZPL-389 麻豆社 BioCapital Invested 2014 Acquired by Novartis in 2016 Location San Francisco, California, USA
